Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -3.00 -2.47% 118.50 718,419 16:29:11
Bid Price Offer Price High Price Low Price Open Price
118.00 119.00 123.50 118.50 120.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.64 -21.34 -8.37 300
Last Trade Time Trade Type Trade Size Trade Price Currency
16:43:51 O 354 118.00 GBX

Avacta (AVCT) Latest News

More Avacta News
Avacta Investors    Avacta Takeover Rumours

Avacta (AVCT) Discussions and Chat

Avacta (AVCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-09-16 15:43:52118.00354417.72O
2021-09-16 15:20:04118.37207245.02O
2021-09-16 15:15:19118.33219259.14O
2021-09-16 15:08:56119.9510,00011,995.00O
2021-09-16 15:06:59118.151,9682,325.19O
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

Avacta Daily Update: Avacta Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 121.50p.
Avacta Group Plc has a 4 week average price of 101.50p and a 12 week average price of 97p.
The 1 year high share price is 290p while the 1 year low share price is currently 90p.
There are currently 253,236,345 shares in issue and the average daily traded volume is 2,091,419 shares. The market capitalisation of Avacta Group Plc is £300,085,068.83.
pwhite73: tickboo - "AVCT snd SNG come end of Oct could be 500p+" It is possible you are right and due to an NDA AVCT has been keeping its powder dry until an official announcement is made that they are going to be the UK's sovereign LFT device. When this happens you'll be able to string all the worst expletives together and aim them at me for costing PIs money or as boysie72 would have it "vulnerable grooming victims". However this game is first and foremost about protecting your capital then making a profit. The indications are that AVCT have not made sufficient traction in the LFT market to justify the current market cap and as such I believe this will be reflected in the share price and shortly. I have no idea how much you have invested in here but you might want to consider divesting some of it away until they publish their interims with a forward looking statement. Once you're happy everything is on track there is nothing to stop you from re-investing.
pwhite73: grosstonnagem - "volsung these are bargain prices IMHO." Compared to prices in the past YES. Compared to its financial performance NO. Revenue to year end 31/12/2020 was £3.6 million with losses of £21.3 million. Novacyt revenue to year end 31/12/2020 was £227 million with profit of £167 million. Avacta market cap is £300 million. Novacyt market cap is £231 million. Both companies had exponential rises in their valuations due to anticipation over the sale of LFTs. Novacyt has delivered because it was an original diagnostic company. Avacta has not delivered because they were never into diagnostics only therapeutics. The AVCT share price has a lot further to fall.
lostabillion: An update on progress at Royal Marsden will be THE key catalyst for #AVCT's share price in the near term. This is high risk. Period. Everyone invested in #AVCT at this stage should be aware of this, and know that this update could land at anytime from now. 3/12
pwhite73: Aman - "It.s like saying a high end Audi wouldn't pass a safety hoop test in the UK.Avcta has a top brand and you, think it won't jump" What I'm saying is that from now on it is the government that will tell the general public if the AVCT LFT is a high end brand not AVCT any longer. As of today there is no evidence AVCT has even attempted to jump through the safety hoop test. That is why the share price is stuck where it is. This may all change in three weeks time or less depending on when the interims are published.
pwhite73: Lostabilliob - "Why he doesn’t just buy I don’t know, any ideas Tickboo?" Let me answer. The interims to 30/06/2021 are due by 30/09/2021 or the shares will be suspended. So they can drop anytime between now and 30/09/2021. As of today I have not read anything from AVCT about LFT sales numbers and even more important government or EU approval for its LFT. Any adverse news in the interims regarding the LFT will cause the share price to halve. That's not a risk I can afford to take with my state pension and attendance allowance.
bmwman3: Similar story at ABDX with AVCT joining forces possibly then Share price forecast for ABDX credit to joshforgold LSEAssumptions: Enterprise Value = 12x gross profit for non-covid related revenue.Enterprise Value = 6x gross profit for covid related revenue. Non covid revenue = £3.5m H1 2021FY2021 Rev = £7mGross Profit Margin 40%GP = £2.7mFactor x12EV=£32.4mAntibody testrevenue = £33 x margin x sales Gross profit margin (est.) 40%Sales (est.) = 1m/year GP = £13.2mFactor x6EV=£79mNow my projections for the lateral flow test sales relies on my firm belief that AVCT will in the next few weeks receive Home Ise Authorisation for their best in class test. At this point their manufacturing agreement with ABDX will kick in and we can expect orders of 4m tests per month. AVCT test revenue = £5 x margin x sales Gross profit margin (est.) 20%Sales (est.) = 48m/year GP = £46mFactor x6EV=£276mWithout any provision for sales of Abingdon's own covid products we reach a the following valuations:Without AVCT sales:£111.4m = £1.15 per shareWith AVCT sales:£387.4m = £3.99 per share
pwhite73: The share drops 4p and Aman/Uma #33609 is at it again, now telling you there's no demand for home testing. Told you all before he's nothing but a coward. When the share price is falling he doesn't want to be on the losing side when the share price is rising he's one of the boys. Leaving that aside he is bang on right about the home testing market. Governments are no longer accepting home test results for travel and clubbing. Employers are no longer accepting home test results so you can skive off work. Both have to be verified with a PCR test. I'm not convinced that AVCT are in any talks with Medusa about a home test product.
viking24: Latest research from John Hopkins inst. indicates a surge in demand for testing in the US, with the demand could approach last winter's demand, which saw Avacta share price in Q1 reach 280p on rapid flow testing est demand alone and the valuation upside to Avacta's share price.The Delta virus is twice as dangerous as the previous variants and the explosion in the growth of the pandemic in the US and Australia etc. Has been 700% week on weekThe leading US test manufacturers Abbot labs and Quidel were quick to cut their production during the summer and are now facing significant shortages and the demand exploding due to new rules and growing cases of fully vaccinated people catching the variant.Europe will see demand taking off again , with with the governments demanded people being fully vaccinated and or tested before entering offices, public places, schools etc.The demand for Rapid LFT will explode again and this time the public will realise that the Pandemic is here for a long time, Avacta will face a massive upside in demand from UK and Europe/Asia, however we will also have fast FDA approval, UK/Europe home/OTC use approval and the previous research reports stating that there is a significant upside to their EPS numbers and valuation price, will very much come true now. The price during the week was as screaming buy and still is, when one consider the earnings upside from the AVA6000 trials.https://www.usatoday.com/story/news/health/2021/08/20/americans-once-again-getting-checked-covid-pace-more-than-1-million-tests-each-day-according-to-john/8152197002/
pwhite73: Aman/Uma - One thing I don't like in a poster is cowardice. When the share price is falling you stick the knife in very subtly. When the share price is rising you jump on the band wagon pretending to be in support of the LTH all along. I don't like that, at least I'm consistent.
grosstonnage: 52 weeks ago AVCT share price broke through 2 pounds for the first time. It happened in the last half hour of trading.
Avacta share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210917 02:14:58